🚀 VC round data is live in beta, check it out!
Kuros Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kuros Biosciences and similar public comparables like Staar Surgical, El.En. Group, Shinva, Medartis and more.
Kuros Biosciences Overview
About Kuros Biosciences
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.
Founded
2016
HQ
Employees
122
Website
Financials (LTM)
EV
$1B
Kuros Biosciences Financials
Kuros Biosciences reported last 12-month revenue of $162M and EBITDA of $19M.
In the same LTM period, Kuros Biosciences generated $140M in gross profit, $19M in EBITDA, and $5M in net income.
Revenue (LTM)
Kuros Biosciences P&L
In the most recent fiscal year, Kuros Biosciences reported revenue of $187M and EBITDA of $16M.
Kuros Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $162M | XXX | $187M | XXX | XXX | XXX |
| Gross Profit | $140M | XXX | $166M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | $19M | XXX | $16M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $5M | XXX | $3M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 2% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kuros Biosciences Stock Performance
Kuros Biosciences has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Kuros Biosciences' stock price is $31.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.2% | XXX | XXX | XXX | $0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKuros Biosciences Valuation Multiples
Kuros Biosciences trades at 7.6x EV/Revenue multiple, and 65.7x EV/EBITDA.
EV / Revenue (LTM)
Kuros Biosciences Financial Valuation Multiples
As of April 20, 2026, Kuros Biosciences has market cap of $1B and EV of $1B.
Equity research analysts estimate Kuros Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kuros Biosciences has a P/E ratio of 229.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 7.6x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 65.7x | XXX | 76.8x | XXX | XXX | XXX |
| EV/EBIT | 110.6x | XXX | 107.3x | XXX | XXX | XXX |
| EV/Gross Profit | 8.8x | XXX | 7.4x | XXX | XXX | XXX |
| P/E | 229.6x | XXX | 383.5x | XXX | XXX | XXX |
| EV/FCF | (992.3x) | XXX | (373.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kuros Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kuros Biosciences Margins & Growth Rates
Kuros Biosciences' revenue in the last 12 month grew by 34%.
Kuros Biosciences' revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $1.3M for the same period.
Kuros Biosciences' rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kuros Biosciences' rule of X is 31% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kuros Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 61% | XXX | 57% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 57% | XXX | 49% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 82% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kuros Biosciences Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kuros Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Staar Surgical | XXX | XXX | XXX | XXX | XXX | XXX |
| El.En. Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Shinva | XXX | XXX | XXX | XXX | XXX | XXX |
| Medartis | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocare | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kuros Biosciences M&A Activity
Kuros Biosciences acquired XXX companies to date.
Last acquisition by Kuros Biosciences was on XXXXXXXX, XXXXX. Kuros Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kuros Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKuros Biosciences Investment Activity
Kuros Biosciences invested in XXX companies to date.
Kuros Biosciences made its latest investment on XXXXXXXX, XXXXX. Kuros Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kuros Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kuros Biosciences
| When was Kuros Biosciences founded? | Kuros Biosciences was founded in 2016. |
| Where is Kuros Biosciences headquartered? | Kuros Biosciences is headquartered in Switzerland. |
| How many employees does Kuros Biosciences have? | As of today, Kuros Biosciences has over 122 employees. |
| Is Kuros Biosciences publicly listed? | Yes, Kuros Biosciences is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Kuros Biosciences? | Kuros Biosciences trades under KURN ticker. |
| When did Kuros Biosciences go public? | Kuros Biosciences went public in 2002. |
| Who are competitors of Kuros Biosciences? | Kuros Biosciences main competitors are Staar Surgical, El.En. Group, Shinva, Medartis. |
| What is the current market cap of Kuros Biosciences? | Kuros Biosciences' current market cap is $1B. |
| What is the current revenue of Kuros Biosciences? | Kuros Biosciences' last 12 months revenue is $162M. |
| What is the current revenue growth of Kuros Biosciences? | Kuros Biosciences revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of Kuros Biosciences? | Current revenue multiple of Kuros Biosciences is 7.6x. |
| Is Kuros Biosciences profitable? | Yes, Kuros Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kuros Biosciences? | Kuros Biosciences' last 12 months EBITDA is $19M. |
| What is Kuros Biosciences' EBITDA margin? | Kuros Biosciences' last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Kuros Biosciences? | Current EBITDA multiple of Kuros Biosciences is 65.7x. |
| What is the current FCF of Kuros Biosciences? | Kuros Biosciences' last 12 months FCF is ($1M). |
| What is Kuros Biosciences' FCF margin? | Kuros Biosciences' last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of Kuros Biosciences? | Current FCF multiple of Kuros Biosciences is (992.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.